To test whether ETV7 altered expression could also affect the sensitivity to other therapeutic treatments for breast cancer, we established two luminal breast cancer-derived cell lines (i.e., MCF7 and T47D, that express very low levels of endogenous ETV7) stably over-expressing ETV7 by lentiviral transduction of a plasmid carrying the ETV7 cDNA or the empty counterpart. This evidence concerns the gene ETV7 and breast cancer.